Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of the announcement issued by Transcenta Holding Limited (registered by way of continuation in the Cayman Islands with limited liability) (Stock Code: 6628) (the “Company,” together with its subsidiaries, the “Group”), make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from or in reliance upon any part of its contents.
According to the announcement dated January 22, 2026, the board of directors reports updates on the measures taken to address the disclaimer of opinion referenced in the Group’s annual report for the year ended December 31, 2024. These measures focus on strengthening the Group’s financial position, enhancing liquidity, and resolving the disclaimer of opinion originally set out in that annual report. Since the updates published on April 22, 2025; July 11, 2025; August 27, 2025; and October 22, 2025, further tangible progress has been achieved across nine areas.
Ongoing discussions with multiple global and regional pharmaceutical companies have advanced for the Group’s lead asset osemitamab, targeting licensing-out or co-development arrangements. Parallel conversations have continued for other pipeline assets, including TST003, TST013, TST198, blosozumab, TST801, and ozekibart, with progress made in out-licensing, joint development models, and the potential formation of NewCos. The Group also continues negotiations with institutional investors and financial intermediaries to bolster its balance sheet.
A significant highlight is a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. for the Highly Intensified Continuous Bioprocessing (HiCB) platform. This arrangement includes possible milestone and royalty payments. The Group has broadened collaborations with cell-culture-media suppliers and further explored opportunities in perfusion and fed-batch culture media supply. Positive discussions have been maintained with banks to renew and extend borrowings, as well as with suppliers to revise payment arrangements.
The Group’s contract development and manufacturing (CDMO) business has secured new domestic and potential international clients, particularly those exploring continuous bioprocessing for complex molecules in development. Internal initiatives to streamline resources have also contributed to cost savings and extended the Group’s cash runway. Although several negotiations and plans remain in progress, management states that the executed measures and the agreement with EirGenix have already enhanced overall financial flexibility.
As of the date of the announcement, the Group indicates that not all plans and actions have been fully realized. Further announcements will be made as circumstances warrant. According to the announcement, the board of directors comprises an executive director, chairman, and chief executive officer; a non-executive director; and four independent non-executive directors, as disclosed. The Company remains committed to resolving the disclaimer of opinion and advancing its core pipeline and CDMO operations.
